Literature DB >> 7890211

Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.

A L Jones1, I H Bangash, J Walker, K J Simpson, N D Finlayson, P C Hayes.   

Abstract

Oral isosorbide-5-mononitrate (Is-5-Mn) was given in doses of 10 and 40 mg acutely and chronically (twice daily for four weeks), allowing a nitrate free interval to 25 patients with cirrhosis. Both 10 mg and 40 mg Is-5-Mn reduced the hepatic venous pressure gradient acutely and chronically, without evidence of tolerance. This was achieved by a reduction in the wedged hepatic venous pressure. The effect on mean azygos blood flow was variable with no significant mean change seen acutely or after chronic use with either dose. The variability was dependent not on the dose used but on the initial azygos flow; the flow in patients with initially low values increased and those with high azygos flows decreased after nitrate challenge. The development of the porto-collateral flow seems an important parameter in predicting haemodynamic response to Is-5-Mn.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890211      PMCID: PMC1382362          DOI: 10.1136/gut.36.1.104

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis.

Authors:  Y T Tsai; F Y Lee; H C Lin; T T Chang; C S Lay; S S Wang; C W Kong; S D Lee; K J Lo
Journal:  Hepatology       Date:  1989-09       Impact factor: 17.425

2.  Effect of sublingual isosorbide dinitrate on wedged hepatic venous pressure in cirrhotics with portal hypertension.

Authors:  H Qureshi; S J Zuberi; A Faruqui
Journal:  Indian J Gastroenterol       Date:  1988-07

3.  Determination of the hepatic blood flow in man by simultaneous use of five test substances measured in two parts of the liver.

Authors:  K Winkler; J A Larsen; T Munkner; N Tygstrup
Journal:  Scand J Clin Lab Invest       Date:  1965       Impact factor: 1.713

4.  Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.

Authors:  P Mols; R Hallemans; C Melot; P Lejeune; R Naeije
Journal:  J Hepatol       Date:  1989-05       Impact factor: 25.083

5.  Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction.

Authors:  B I Jugdutt; J W Warnica
Journal:  Am J Cardiol       Date:  1989-09-15       Impact factor: 2.778

6.  Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: evidence for an impaired cardiopulmonary baroreflex function.

Authors:  R Moreau; D Roulot; A Braillon; C Gaudin; A Hadengue; Y Bacq; D Lebrec
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

7.  Biotransformation of glyceryl trinitrate and isosorbide dinitrate in vascular smooth muscle made tolerant to organic nitrates.

Authors:  C J Slack; B E McLaughlin; J F Brien; G S Marks; K Nakatsu
Journal:  Can J Physiol Pharmacol       Date:  1989-11       Impact factor: 2.273

Review 8.  Mechanisms of nitrate action and vascular tolerance.

Authors:  H L Fung; S Chong; E Kowaluk
Journal:  Eur Heart J       Date:  1989-05       Impact factor: 29.983

9.  Effect of sublingual isosorbide dinitrate in portal hypertension.

Authors:  S J Bhatia; H Deshmukh; P Abraham; A V Shah; J A Vontivillu; D H Jagasia; R H Kothari
Journal:  Indian J Gastroenterol       Date:  1990-04

10.  Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.

Authors:  J Cervinka; V Kordac; M Kalab
Journal:  J Int Med Res       Date:  1989 Nov-Dec       Impact factor: 1.671

View more
  1 in total

1.  Modulation of hepatic perfusion did not improve recovery from hepatic outflow obstruction.

Authors:  J Arlt; W Wei; C Xie; A Homeyer; U Settmacher; U Dahmen; O Dirsch
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-26       Impact factor: 2.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.